trending Market Intelligence /marketintelligence/en/news-insights/trending/axp47svww0kruq_ls5onjq2 content esgSubNav
In This List

Alder Biopharmaceuticals director resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alder Biopharmaceuticals director resigns

Stephen Dow has resigned as director of Alder Biopharmaceuticals Inc., effective May 24.

Dow did not express any disagreement on any matter relating to the company's operations, policies or practices, Alder Biopharmaceuticals stated in a Form 8-K filing.

Bothell, Wash.-based Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutic antibodies in the U.S., Australia and Ireland.